title: Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
abstract: OBJECTIVE
  Unfractionated heparin (UFH) and enoxaparin (low molecular weight heparin) constitute fundamental therapies in the treatment of patients with acute coronary syndrome (ACS). Since enoxaparin appears to offer clinical advantages over UFH in managing ACS, markers of thrombin generation, endothelial function and acute phase response could manifest different responses to UFH or enoxaparin. The purpose of the present study was to investigate the effect that treatment with either UFH or enoxaparin has on plasma hemostatic markers in 24 patients with ACS.
  
  
  METHODS
  The patients were randomized to receive 5,000 IU intravenous bolus and continuous infusion of 18 IU/Kg/h UFH (n=11) or 1 mg/kg/12h subcutaneous enoxaparin (n=13). The plasma levels of fibrinogen (Fg), prothrombin fragment 1+2 (F1+2), thrombin antithrombin complex (TAT), von Willebrand factor (vWF), tissue factor (TF) and tissue factor pathway inhibitor (TFPI) were assayed at admission and 6, 12, 24 and 48 hours after heparin treatment.
  
  
  RESULTS
  Upon admission, UFH and enoxaparin patients showed a significant increase in all the hemostatic parameters measured with respect to the levels in the control subjects. In comparison with the baseline levels of the UFH- and enoxaparin-treated patients, Fg showed a significant increase at 48 h and TFPI at 6, 12 and 24 hours. However, at 48 hours TFPI levels were not significantly higher than the basal values. There were no significant changes in F1+2, TAT, vWF or TF.
  
  
  CONCLUSIONS
  Markers of thrombin generation, endothelial function and acute-phase reactants manifest a similar response to UFH and enoxaparin. An increase in thrombin generation may be a result of persistently activated inflammatory and endothelial processes, despite UFH and enoxaparin treatment.
authors.affiliation: Research Center, La Fe University Hospital, Valencia, Spain. reganon_ede@gva.es
authors.forename: V
authors.initials: V
authors.lastname: Vila
authors.forename: V
authors.initials: V
authors.lastname: Martínez-Sales
authors.forename: E
authors.initials: E
authors.lastname: Réganon
authors.forename: E
authors.initials: E
authors.lastname: Peris
authors.forename: F
authors.initials: F
authors.lastname: Perez
authors.forename: M
authors.initials: M
authors.lastname: Ruano
authors.forename: J
authors.initials: J
authors.lastname: Aznar
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D017984:Enoxaparin / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D006490:Hemostatics / Q000097:blood*; D006493:Heparin / Q000008:administration & dosage / Q000494:pharmacology*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D013577:Syndrome
chemical_list: D017984:Enoxaparin; D006490:Hemostatics; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin